Your endo is doing a more thorough job, full stop. Here's why: Standard lipid panel gives you LDL-C (cholesterol concentration). This is like counting the number of passengers on buses without counting the buses. You could have 10 buses with 5 passengers each or 50 buses with 1 passenger each — same total passengers, very different risk. NMR LipoProfile counts the actual LDL particles (LDL-P). An LDL-P of 1380 means you have MORE particles than ideal even though each one isn't carrying that much cholesterol. More particles = more chances for particles to penetrate arterial walls = more atherosclerotic risk. Your endo is also checking: - Fasting insulin + HOMA-IR: Measures insulin resistance directly, not just glucose control. You can have "normal" glucose with sky-high insulin (compensated IR). This is way more nuanced than A1C alone. - C-peptide: Measures how much insulin YOUR pancreas makes. Important for understanding your metabolic health trajectory. - Lipase: Monitors pancreatic safety on GLP-1 - hs-CRP: Inflammation marker with cardiovascular significance - Thyroid: Screening for GLP-1 thyroid concerns (low risk but worth monitoring) Your PCP's panel is a basic annual screening. Your endo's panel is metabolic optimization monitoring. Both are valid for their purposes but if you can only pick one approach, go with the endo's.

I'll push back slightly. Your PCP isn't "wrong" — they're doing standard of care screening which is appropriate for the general population. NMR LipoProfile, fasting insulin, and C-peptide are not standard guidelines-based tests for most patients. They're advanced testing that many insurance plans won't cover. That said, for someone on GLP-1 therapy actively managing metabolic disease, your endo's approach IS better. It's just not what PCPs are trained to do or what guidelines tell them to order for routine care. The solution isn't "who's right" — it's coordination. Ask your endo to send a note to your PCP explaining what they're monitoring and why. Ask your PCP to defer metabolic lab ordering to the endo. This prevents duplicate testing and conflicting interpretations.

That's a great point about coordination. They're in different health systems so they don't share records, which is part of the problem. I've been manually carrying results between them. Another example of conflicting interpretation: my A1C is 5.4%. PCP says "perfect, no diabetes concerns." Endo says "your A1C is good but your fasting insulin is 18 mIU/L which is still elevated (ideal <8) and your HOMA-IR is 4.1 (ideal <1.0, insulin resistant >2.5). You still have significant insulin resistance that the A1C is masking because the semaglutide is compensating." That's a completely different clinical picture depending on who you listen to.

Your endo is 100% right on this one and it illustrates exactly why fasting insulin matters. A1C of 5.4% + Fasting insulin of 18 + HOMA-IR of 4.1 = compensated insulin resistance Your body is producing 2-3x the normal amount of insulin to keep your blood sugar at 5.4%. The semaglutide is helping by enhancing insulin sensitivity and secretion patterns, but the underlying insulin resistance hasn't fully resolved yet. This is actually useful information because it tells you: 1. If you stop sema, your glucose will likely spike because you're still IR 2. You have more metabolic healing to do (continued weight loss, exercise, dietary improvement) 3. Your cardiovascular risk is higher than A1C alone suggests Here's a simplified HOMA-IR interpretation: | HOMA-IR | Interpretation | |---------|---------------| | < 1.0 | Optimal insulin sensitivity | | 1.0 - 1.9 | Normal range | | 2.0 - 2.5 | Early insulin resistance | | 2.5 - 5.0 | Significant insulin resistance | | > 5.0 | Severe insulin resistance | At 4.1, you're solidly insulin resistant despite "normal" glucose and A1C. This is the hidden iceberg that standard labs miss.